MOH — authorised 12 August 2013
- Marketing authorisation holder: VIIV HLTHCARE
- Status: likely_approved
MOH authorised Tivicay on 12 August 2013
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 12 August 2013.
VIIV HLTHCARE holds the Israeli marketing authorisation.